You are here:
26 July 2018 / deal

Acquisition of Takeda Chromo by Shanghai Pharmaceuticals Holding Co.

Loyens & Loeff advised Shanghai Pharmaceuticals on the acquisition of Takeda Chromo Beteiligungs AG.

The Belgian ‘Cayman tax’ and its impact on wealth and estate planning in Belgium

Shanghai Pharmaceuticals Holding Co. (Hong Kong) announced the entering into a share purchase agreement with Takeda AG, a wholly-owned subsidiary of Takeda Japan (listed on the Tokyo Stock Exchange) to acquire 100% of the issued and outstanding share capital of Takeda Chromo Beteiligungs AG. Upon completion of the USD 144 million acquisition, Shanghai Pharmaceuticals will increase its direct and indirect shareholding in Techpool Bio-pharma Co., Ltd, a global leader in natural urine protein drugs, to approximately 67,14%. The acquisition is, among other conditions, still subject to approval by the China National Market Supervision Administration.

Loyens & Loeff advised Shanghai Pharmaceuticals Holding Co. as Swiss transaction counsel on this acquisition. The team was led by partner Marco Toni (Corporate / M&A, Switzerland) and consisted of Jana Bieli (Corporate / M&A, Switzerland) and Rebecca Kühne (Tax, Switzerland).

 



Switzerland: Legal considerations relating to the COVID-19

This article aims to highlight the most important points in this context and to clarify legal issues in the elaboration of possible courses of action. read more

Switzerland ranked in the IFLR1000 2021 guide

IFLR1000, the guide to the world’s leading financial and corporate law firms, has released its 2021 rankings and we are delighted that our Swiss Corporate /... read more

Swiss Restructuring & Insolvency in a nutshell

Ever-changing market conditions require businesses to continuously monitor their earnings and liquidity situation as well as their debt structure. read more